ReviewToxins2018
Role of Uremic Toxins for Kidney, Cardiovascular, and Bone Dysfunction.
Review in Toxins, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 82 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
82 citing papers in PubMed, 1 synthesis or guideline pooled it, 133 citations in OpenAlex.
- Protein-bound uremic toxin lowering strategies in chronic kidney disease: a systematic review and meta-analysis.Journal of nephrology · 2021Pooled it
- Evaluating the antioxidant and anti-inflammatory effect of melatonin in pediatric hemodialysis patients: a randomized, placebo-controlled trial.Scientific reports · 2026Trial
- Cardiovascular Risk Comparison between Expanded Hemodialysis Using Theranova and Online Hemodiafiltration (CARTOON): A Multicenter Randomized Controlled Trial.Scientific reports · 2021Trial
- Indoxyl sulfate exacerbates chronic inflammation and susceptibility to severe infection via modulating T-cell CD73/adenosine signaling in chronic kidney disease.Renal failure · 2026Article
- Rehabilitation Exercise Behaviors in Patients Undergoing Peritoneal Dialysis: A Mixed-Methods Study on Multidimensional Determinants.Archives of rehabilitation research and clinical translation · 2026Article
- Early Post-Transplant Changes in Nutritional Status Predict Long-Term Graft Loss and Mortality.Journal of clinical medicine · 2026Article
- Article
- 4D automatic left atrial quantification technology-recommended for evaluating the impact of peritoneal dialysis on the left atrium of chronic kidney disease stage 5 patients.Quantitative imaging in medicine and surgery · 2026Article
- Haikunshenxi capsule alleviates renal fibrosis in chronic kidney disease via modulation of indoxyl Sulfate-Aryl hydrocarbon receptor signaling.Frontiers in pharmacology · 2026Article
- Article
- Furosemide and Serum Protein-Bound Uremic Toxin Concentrations in Patients With CKD.Kidney international reports · 2025Article
- Cardiovascular Risk and Its Presentation in Chronic Kidney Disease.Journal of clinical medicine · 2025Review
- Indole metabolism and its role in diabetic macrovascular and microvascular complications.American heart journal plus : cardiology research and practice · 2025Review
- Impact of using oral spherical carbon adsorbent in predialysis chronic kidney disease period on cardiovascular outcome after dialysis therapy.Scientific reports · 2025Article
- Benefits and Pitfalls of Uraemic Toxin Measurement in Peritoneal Dialysis.Journal of clinical medicine · 2025Review
- Chronic Kidney Disease and Osteoarthritis: Current Understanding and Future Research Directions.International journal of molecular sciences · 2025Review
- Validation of an LC-HRMS Method for Quantifying Indoxyl Sulfate andMolecules (Basel, Switzerland) · 2025Article
- UnravelingFrontiers in pharmacology · 2025Review
- The gut-heart axis: unveiling the roles of gut microbiota in cardiovascular diseases.Frontiers in cardiovascular medicine · 2025Review
- Investigating the cause of cardiovascular dysfunction in chronic kidney disease: capillary rarefaction and inflammation may contribute to detrimental cardiovascular outcomes.Basic research in cardiology · 2024Article
22 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With decreasing kidney function, cardiovascular disease (CVD) and mineral bone disorders frequently emerge in patients with chronic kidney disease (CKD). For these patients, in addition to the traditional risk factors, non-traditional CKD-specific risk factors are also associated with such diseases and conditions. One of these non-traditional risk factors is the accumulation of uremic toxins (UTs). In addition, the accumulation of UTs further deteriorates kidney function. Recently, a huge number of UTs have been identified. Although many experimental and clinical studies have reported associations between UTs and the progression of CKD, CVD, and bone disease, these relationships are very complex and have not been fully elucidated. Among the UTs, indoxyl sulfate, asymmetric dimethylarginine, and
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.